Ph.D., Principal Scientist, Innovate Oncology, Evotec
Biography
As an oncology researcher with 20 years of experience, he is leading cancer-focused projects at Evotec, a drug discovery alliance and development partnership company. He is managing a multi-disciplinary team to identify new therapeutics to treat colorectal cancer (CRC). By datamining Indivumed’s “Indivutype” multi-omics cancer database using Evotec’s bioinformatics analysis platform “PanHunter” the first targets have recently been uncovered and progressed towards the development of truly first-in-class therapeutics for the treatment of CRC using Evotec’s multimodality drug discovery and development platforms. After completing his Masters at the University of Vienna (Austria), he obtained his Ph.D. from the University of Basel (Switzerland), followed by postdoctoral training focused on kinase signaling. By combining structure, biochemistry, molecular and cell biology approaches with fly and mouse genetics, he then led a research group at the UCL Cancer Institute (London, UK), centered on dissecting key molecular steps of the Hippo tissue growth and regeneration pathway.
Session Abstract – PMWC 2020 Silicon Valley
Track 2 - January 24 2.30 P.M.-3.00 P.M.
Genomic data and single-level omics approaches have limited impact on precision oncology as they lack the resolving power to establish the relationship between molecular signatures and phe-notypic manifestation of cancer. This session will illustrate a multiomics database when coupled with machine learning technology and AI can advance novel cancer discoveries.
